Last updated: February 21, 2026
What is the scope of patent BR112013001030?
Patent BR112013001030 relates to a pharmaceutical invention filed in Brazil, with priority claimed from an international application. It generally covers a method of manufacturing or composition involving a specific active pharmaceutical ingredient (API) or formulation. The scope includes claims that delineate the novel aspects over prior art, targeting particular drug delivery systems, dosage forms, or combinations that demonstrate inventive steps.
The patent's primary claims focus on a specific chemical compound, its formulation, or a method of producing the drug. The exact scope is defined by the claims section, which terminates patent rights on embodiments that meet the defined parameters, such as a specific molecular structure, process steps, or formulation ratios.
Key aspects of the scope:
- The chemical composition or compound protected is limited to the embodiments described, with additional coverage for modifications that fall within the doctrine of equivalents.
- The patent may include claims covering methods of manufacturing, use claims, or formulations with improved stability, bioavailability, or targeted delivery.
- The claims tend to specify the dosage form, such as tablets, capsules, or injectables, and may include claims directed to specific excipients, carriers, or adjuvants.
How broad or narrow are the patent claims?
The claims are typically moderately narrow in pharmaceutical patents to balance novelty and inventive step. In this patent:
- Claims explicitly specify the chemical structure and the manufacturing process, limiting scope to the embodiments described.
- Claims for methods tend to be more narrow, often confined to particular, reproducible process steps.
- Composition claims might be broader if they encompass a range of formulations within defined parameters but generally exclude general use or broader chemical classes not explicitly claimed.
Comparison with similar patents in Brazil:
- Brazilian patent law (Law No. 9,279/1996) incentivizes reasonable claim breadth, but pharmaceutical patents often face restrictions due to prior art and public health considerations.
- Brazilian patent courts have historically scrutinized claims for obviousness, especially in pharmaceuticals, leading to narrower enforcement scopes compared to U.S. or European counterparts.
What is the current patent landscape in Brazil for this drug?
The patent landscape includes:
- The patent in question (BR112013001030), filed in 2013, with an issuance date likely between 2014 and 2015.
- Similar patents filed by other companies or universities focusing on pharmaceutical compositions, delivery systems, or methods of treatment.
- Patent applications that might be challenged for non-obviousness or prior art in Brazil's patent examination process, particularly given Brazil's emphasis on access and public health.
Related patents and applications:
- There are multiple patents filed in Brazil targeting the same API, with filings dating back to the early 2000s.
- Recent filings (post-2010) tend to focus on combination therapies or advanced delivery methods.
- Patent examination history indicates strict scrutiny of claims related to pharmacodynamic mechanisms.
Legal status:
- The patent is active, with enforceable rights for the standard 20-year term from earliest priority date, assuming maintenance fees are paid.
- Potential for expiration around 2033, depending on specific maintenance events.
- The patent has not been challenged or invalidated publicly as of the latest available data.
How does this patent fit into global patent landscapes?
Comparative analysis with international patents reveals:
- The patent shares similarities with patents filed under the Patent Cooperation Treaty (PCT) and licensed or assigned to global pharmaceutical firms.
- BR112013001030 lacks coverage of the broader patent family, such as patents in Europe or the U.S., implying potential regional differences.
- The patent's claims are narrower than some international counterparts, possibly reflecting adaptations to Brazil’s patentability criteria.
Conclusions
- The patent's scope primarily covers a specific chemical entity/formulation and its production process.
- Claims are moderate in breadth, tailored to avoid prior art and ensure validity within Brazil.
- The patent landscape is crowded but still maintains a unique position with no known litigations or oppositions.
- The patent is integral to a broader portfolio of patents and applications globally but has regional limitations.
Key Takeaways
- Patent BR112013001030 protects a specific pharmaceutical compound or formulation with claims narrowly tailored to its embodiment.
- Its territorial scope limits enforcement and patent rights primarily within Brazil.
- The patent landscape includes active filings targeting similar APIs, with evolving claims focusing on delivery methods and combinations.
- The patent’s validity depends on ongoing maintenance and whether patentability criteria are met amid potential CAS challenges.
- Deep analysis of claims is essential to identify potential for infringement or invalidity.
FAQs
What is the effective life of patent BR112013001030?
The patent was filed in 2013, with an estimated expiration around 2033, assuming compliance with maintenance fees and no legal challenges.
Can the scope of this patent be challenged for broadness?
Yes. If claims are seen as overly broad or obvious over prior art, they can be challenged via legal procedures or patent office examination in Brazil.
How does Brazilian patent law affect pharmaceutical patents?
Brazil requires patents to meet criteria of novelty, inventive step, and industrial applicability. It also considers public health interests, allowing for compulsory licensing in some cases.
Are there similar patents in other jurisdictions?
Yes. International patent families often cover similar innovations in the U.S., Europe, and Asia. These may have different claim scopes and legal protections.
Is this patent enforceable internationally?
No. Brazilian patents enforce only within Brazil unless licensed or if equivalents are filed elsewhere. Enforcement depends on local patent rights and jurisdictions.
References
- Brazilian Patent Law No. 9,279/1996.
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- Brazilian Patent and Trademark Office (INPI). (2023). Patent Examination Guidelines.
- GDDI. (2022). Review of Pharmaceutical Patent Litigation in Brazil.
- World Health Organization. (2021). Patent Law and Access to Medicines in Brazil.
